| Literature DB >> 29568758 |
Bin Jin1, Zhengchen Jiang1, Sanyuan Hu1, Gang Du1, Binyao Shi1, Du Kong1, Jinhuan Yang1.
Abstract
OBJECTIVE: To describe the surgical procedures of laparoscopic caudate lobectomy and analyze its clinical efficiency for treating cancer.Entities:
Mesh:
Year: 2018 PMID: 29568758 PMCID: PMC5820552 DOI: 10.1155/2018/5848309
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Port position for laparoscopic isolated caudate lobectomy.
Figure 2Transection of the CL branches from the IVC or porta hepatis. (a),(b) Dissection of SHV. (c), (d) Dissection of Glissonian branches of the CL.
Figure 3Transection of the CL parenchyma and technique of exposure to surgical vision. (a)–(c) Dissection of left or right of caudate lobe. (d) Place the S-shaped retractor to pull the hepatoduodenal ligament.
Results of seven patients undergoing laparoscopic caudate lobectomy.
| Patient no. | Age/gender | HBV | Cirrhosis | Other diseases | Resection | Tumor | Tumor | Operation time (min) | EBL (ml) | HPCT (min) | POS | Drainage time (days) | Conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (1) | 29/M | − | − | CL | HCH | 62 | 85 | 50 | 15 | 7 | 0 | - | |
| (2) | 23/F | − | − | Chronic gastritis | CL | FNH | 51 | 205 | 350 | 6 | 4 | - | |
| (3) | 59/F | + | + | Coronary disease | CL | HCC | 52 | 140 | 100 | 7 | 5 | - | |
| (4) | 50/F | − | − | CL | HCH | 51 | 115 | 100 | 21 | 10 | 5 | - | |
| (5) | 58/M | + | + | CL | HCC | 61 | 150 | 200 | 20 | 15 | 13 | - | |
| (6) | 47/F | − | − | Hypertension | CL | HCH | 52 | 75 | 50 | 8 | 4 | - | |
| (7) | 48/M | + | − | Renal clear cell carcinoma | CL | HCC | 65 | 420 | 50 | 14 | 12 | - | |
| (8) | 50/M | + | + | CL | HCC | 52 | 130 | 60 | 8 | 5 | - | ||
| (9) | 54/F | + | − | CL | HCC | 49 | 90 | 50 | 9 | 4 | - | ||
| (10) | 49/F | − | − | CL | HCH | 51 | 100 | 55 | 12 | 6 | - | ||
| (11) | 60/F | + | + | CL | HCC | 54 | 80 | 60 | 8 | 5 | - | ||
| (12) | 51/M | + | + | CL | HCC | 61 | 100 | 50 | 6 | 5 | - |
CL: caudate lobe; PMT, HPCT: hepatic pedicle clamping time; HCH: hepatic hemangioma; HCC: hepatocellular carcinoma; EBL: estimated blood loss; POS: postoperative hospital stay; HCA: hepatocellular adenoma.
Perioperative data and follow-up outcomes.
| No. | Presurgery | Postoperative day 1 | Postoperative day 3 | Postoperative day 5 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT | AST | TBIL | ALB | PT | INR | ALT | AST | TBIL | ALB | PT | INR | ALT | AST | TBIL | ALB | ALT | AST | TBIL | ALB | |
| (1) | 14 | 17 | 8.4 | 42.2 | 12 | 1.14 | 126 | 62 | 21.1 | 42.9 | 13.7 | 1.3 | 60 | 40 | 18 | 42.8 | 23 | 26 | 14.8 | 42.8 |
| (2) | 6 | 12 | 10.6 | 44.4 | 11.1 | 1.06 | 89 | 76 | 89 | 76 | 12.3 | 1.15 | 59 | 27 | 7.1 | 42 | 29 | 17 | 7.4 | 40.9 |
| (3) | 14 | 22 | 10.5 | 42.8 | 11.9 | 1.13 | 90 | 110 | 11 | 35.7 | 13.3 | 1.26 | 69 | 55 | 14.9 | 41.1 | 38 | 24 | 14.2 | 42.7 |
| (4) | 15 | 20 | 9.9 | 45 | 12.4 | 1.18 | 90 | 72 | 13.5 | 42.2 | 12.1 | 1.15 | 44 | 24 | 11.4 | 39.7 | 27 | 17 | 10.5 | 41 |
| (5) | 13 | 19 | 10.1 | 44.3 | 12 | 1.14 | 53 | 73 | 16.8 | 36.1 | 13.8 | 1.32 | 23 | 24 | 26.1 | 34.7 | 13 | 11 | 21.3 | 38.4 |
| (6) | 17 | 21 | 8.3 | 45.1 | 11.6 | 1.10 | 50 | 45 | 9.7 | 39 | 12.4 | 1.17 | 27 | 17 | 11.3 | 40.2 | 38 | 27 | 7.9 | 41.6 |
| (7) | 20 | 21 | 13.9 | 42.9 | 11.1 | 1.06 | 86 | 75 | 20.1 | 42.8 | 12.6 | 1.2 | 50 | 30 | 24.6 | 39.9 | 29 | 26 | 10.6 | 37 |
| (8) | 17 | 18 | 10.3 | 45.2 | 11.2 | 1.13 | 73 | 82 | 19.5 | 42.3 | 12.3 | 1.15 | 48 | 34 | 15.6 | 43.5 | 25 | 14 | 12.5 | 47 |
| (9) | 10 | 15 | 8.5 | 43.5 | 12 | 1.11 | 81 | 75 | 17.4 | 41.5 | 12.6 | 1.14 | 60 | 29 | 14.7 | 42.9 | 19 | 18 | 11.8 | 45.3 |
| (10) | 9 | 20 | 11.0 | 44.9 | 11.5 | 1.09 | 65 | 69 | 16.4 | 43.9 | 11.9 | 1.14 | 35 | 37 | 13.2 | 44.2 | 24 | 23 | 10.3 | 45.3 |
| (11) | 13 | 19 | 9.3 | 43.7 | 12.2 | 1.12 | 68 | 66 | 15.2 | 43.2 | 12.5 | 1.19 | 59 | 36 | 14.1 | 43.9 | 25 | 19 | 10.5 | 44.1 |
| (12) | 15 | 21 | 8.9 | 44.0 | 11.5 | 1.08 | 72 | 70 | 16.5 | 42.9 | 12.1 | 1.15 | 48 | 40 | 15.2 | 44.1 | 21 | 17 | 9.8 | 45 |
ALT: alanine aminotransferase (U/L); AST: aspartate transaminase (U/L); TBIL: total bilirubin (umol/L); ALB: albumin (g/L); PT: prothrombin time (s); INR: international normalized ratio.
Reported cases of laparoscopic isolated caudate lobectomy.
| Patient no. | First author | Year | Case | Tumor origin | Tumor size (mm) | Operation time (min) | EBL (ml) | POS (day) |
|---|---|---|---|---|---|---|---|---|
| (1) | Araki [ | 2006 | 2 | Metastases (2) | 105–150 | 100–200 | 8, 10 | |
| (2) | Cheung [ | 2007 | 1 | HCH | 52 | 160 | 50 | 8 |
| (3) | Inamori [ | 2007 | 7 | Benign (5), HCC (2) | ||||
| (4) | Lai [ | 2011 | 4 | HCH (3), hepatolithiasis (1) | ||||
| (5) | Kyriakides [ | 2012 | 3 | 180–300 | 150–400 | |||
| (6) | Jin [ | 2012 | 1 | HCA | 77 | 50 | ||
| (7) | Cai [ | 2013 | 1 | Benign | 60 | |||
| (8) | Gringeri [ | 2014 | 7 | HCC (4), metastases (3) | 45 | 210–345 | 10–1000 | |
| (9) | Zarzavadjian Le Bian [ | 2014 | 2 | HCC | 15 | 137, 150 | 137, 150 | 4, 5 |
| (10) | Salloum [ | 2014 | 1 | HCA | 60 | 270 | 200 | |
| (11) | Kokkalera [ | 2014 | 1 | Metastases | 140 | 80 | ||
| (12) | Ho [ | 2015 | 2 | Metastases | 140 | 80 | 6, 8 | |
| (13) | Oh [ | 2016 | 5 | Metastases (4), FNH (1) | 35 | 240 (180–345) | 200 (50–700) | 6–14 |
| (14) | Yoon [ | 2016 | 6 | HCC (1), CCC (1), metastases (1) | 2.65 (0.9–5.1) | 382 (168–615) | 242.5 (120–360) | 7 (6–13) |
| (15) | Jiang [ | 2016 | 15 | Metastases (12), HCC (1), benign (2) | 50 | 150 (60–480) | 75 (0–500) | 8 ± 6.5 |
| (16) | Chen [ | 2016 | 1 | HCC | 45 | 190 | 90 | |
| (17) | Asahara [ | 2016 | 1 | HCC | 16 | 270 | 270 | |
| (18) | Ishizawa [ | 2016 | 1 | Metastases | 20 | 180 | 220 | |
| (19) | Koffron [ | 2016 | 4 | HCC (1), Metastases (1), HCH (2) | 11.8 (1.2–20) | 185 (155–350) | 250 (200–600) | 7 (4–11) |
HCA: hepatocellular adenoma; HCH: hepatic hemangioma; HCC: hepatocellular carcinoma; EBL: estimated blood loss; POS: postoperative hospital stay.
Reported cases of laparoscopic isolated caudate lobectomy.
| No | First author | Mean op time (min) | Mean EBL (ml) |
|---|---|---|---|
| 1 | Araki [ | 127.5 | 150 |
| 2 | Cheung [ | 160 | 50 |
| 6 | Jin [ | 77 | 50 |
| 9 | Zarzavadjian Le Bian [ | 143.5 | 143.5 |
| 10 | Gringeri [ | 270 | 200 |
| 11 | Kokkalera [ | 140 | 80 |
| 12 | Ho [ | 140 | 80 |
| 13 | Oh [ | 240 | 200 |
| 14 | Yoon [ | 382 | 242.5 |
| 15 | Jiang [ | 150 | 75 |
| 16 | Chen [ | 190 | 90 |
| 17 | Asahara [ | 270 | 270 |
| 18 | Ishizawa [ | 180 | 220 |
| 19 | Koffron [ | 185 | 250 |
|
| |||
| Other reports ( | 189.64 ± 77.77 | 150.07 ± 79.38 | |
| This study ( | 140.8 ± 95.34 | 97.92 ± 90.54 | |
|
|
| ||
HCA: hepatocellular adenoma; CCC: cholangiocarcinoma; HCH: hepatic hemangioma; HCC: hepatocellular carcinoma; EBL: estimated blood loss.